Wechselwirkungen · Camzyos
CAMZYOS 2.5 mg hard capsules CAMZYOS 5 mg hard capsules CAMZYOS 10 mg hard capsules CAMZYOS 15 mg hard capsules · Abschnitt 4.5 · PDF-Seite 10
HOS-147601 · Präparat HOS-099694
CYP3A4 inhibitors The effect of strong CYP3A4 inhibitors on the PK of mavacamten was not investigated in a clinical drug-drug interaction study. Co-administration of mavacamten with a strong CYP3A4 inhibitor (itraconazole) in CYP2C19 normal metabolisers is expected to result in an increase in mavacamten plasma concentration of up to 59% and 40% in AUC0-24 and Cmax, respectively. Co-administration of mavacamten with a moderate CYP3A4 inhibitor (verapamil) in CYP2C19 normal metabolisers resulted in an increase in mavacamten plasma concentration of 16% and 52% in AUCinf and Cmax, respectively. This change was not considered clinically significant.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): itraconazole (HOS-084516) verapamil (HOS-090602)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-06-02T15:36:00Z · SHA-256 9132b2e8e8aaa16319c50ba4cee221a3197217762e259ff316f0a88969d8e68f · Passage 186bc56df3e4b0931f234b8389718998624263c343c7e0e4868bcb4864bb3a2b · Zeichen 2313–2965 im Abschnitt